Movement Alert｜TG Therapeutics Rises 5.01% in Regular Trading, Rebounding as Market Re-Prices Q2 Revenue Beat and Raised Full-Year Guidance

Market Focus08-05 03:36

On August 5, TG Therapeutics rose 5.01% in regular trading, trading at approximately $48.49 per share, with turnover of approximately $90.52 million.

The rebound follows the market's reassessment of the company's Q2 results, which showed total global revenue of approximately $240 million, exceeding the consensus estimate of $230 million. The company simultaneously raised its full-year BRIUMVI revenue guidance. The stock had previously declined approximately 7% after reporting Q2 earnings per share of just $0.05, significantly missing the analyst consensus estimate of $0.33 — representing an 84.85% shortfall and marking the third consecutive quarter of EPS missing expectations.

The current recovery suggests investors are shifting focus toward the top-line strength and improved revenue outlook. TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell mediated diseases, with its core product BRIUMVI approved in the U.S., EU, and UK for relapsing forms of multiple sclerosis. The company has also been expanding BRIUMVI's pipeline into myasthenia gravis and treatment-resistant schizophrenia.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136044206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 03:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136044206","market":"us","top_or_hot":-1,"title":"Movement Alert｜TG Therapeutics Rises 5.01% in Regular Trading, Rebounding as Market Re-Prices Q2 Revenue Beat and Raised Full-Year Guidance","media":"Market Focus","content":"<p><p>On August 5, TG Therapeutics rose 5.01% in regular trading, trading at approximately $48.49 per share, with turnover of approximately $90.52 million.</p><p>The rebound follows the market's reassessment of the company's Q2 results, which showed total global revenue of approximately $240 million, exceeding the consensus estimate of $230 million. The company simultaneously raised its full-year BRIUMVI revenue guidance. The stock had previously declined approximately 7% after reporting Q2 earnings per share of just $0.05, significantly missing the analyst consensus estimate of $0.33 — representing an 84.85% shortfall and marking the third consecutive quarter of EPS missing expectations.</p><p>The current recovery suggests investors are shifting focus toward the top-line strength and improved revenue outlook. TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell mediated diseases, with its core product BRIUMVI approved in the U.S., EU, and UK for relapsing forms of multiple sclerosis. The company has also been expanding BRIUMVI's pipeline into myasthenia gravis and treatment-resistant schizophrenia.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜TG Therapeutics Rises 5.01% in Regular Trading, Rebounding as Market Re-Prices Q2 Revenue Beat and Raised Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜TG Therapeutics Rises 5.01% in Regular Trading, Rebounding as Market Re-Prices Q2 Revenue Beat and Raised Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-05 03:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 5, TG Therapeutics rose 5.01% in regular trading, trading at approximately $48.49 per share, with turnover of approximately $90.52 million.</p><p>The rebound follows the market's reassessment of the company's Q2 results, which showed total global revenue of approximately $240 million, exceeding the consensus estimate of $230 million. The company simultaneously raised its full-year BRIUMVI revenue guidance. The stock had previously declined approximately 7% after reporting Q2 earnings per share of just $0.05, significantly missing the analyst consensus estimate of $0.33 — representing an 84.85% shortfall and marking the third consecutive quarter of EPS missing expectations.</p><p>The current recovery suggests investors are shifting focus toward the top-line strength and improved revenue outlook. TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell mediated diseases, with its core product BRIUMVI approved in the U.S., EU, and UK for relapsing forms of multiple sclerosis. The company has also been expanding BRIUMVI's pipeline into myasthenia gravis and treatment-resistant schizophrenia.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1136044206","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136044206","pubTimestamp":1785872191,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 5, TG Therapeutics rose 5.01% in regular trading, trading at approximately $48.49 per share, with turnover of approximately $90.52 million.The rebound follows the market's reassessment of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"走势警报|TG Therapeutics 常规交易中上涨 5.01%，随着市场重新定价第二季度收入超出预期并上调全年指引而反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"On August 5, TG Therapeutics rose 5.01% in regular trading, trading at approximately $48.49 per share, with turnover of approximately $90.52 million.The rebound follows the market's reassessment of the company's Q2 results, which showed total global revenue of approximately $240 million, exceeding the consensus estimate of $230 million. The company simultaneously raised its full-year BRIUMVI revenue guidance. The stock had previously declined approximately 7% after reporting Q2 earnings per share of just $0.05, significantly missing the analyst consensus estimate of $0.33 — representing an 84.85% shortfall and marking the third consecutive quarter of EPS missing expectations.The current recovery suggests investors are shifting focus toward the top-line strength and improved revenue outlook. TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell mediated diseases, with its core product BRIUMVI approved in the U.S., EU, and UK for relapsing forms of multiple sclerosis. The company has also been expanding BRIUMVI's pipeline into myasthenia gravis and treatment-resistant schizophrenia.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136044206","isCrawlerRequest":true}